---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-25-000011"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:26:03.987165+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q4 net sales $93M (+7% YoY), Adjusted EBITDA margin 21%, guides high-single-digit growth for 2025

## Summary
- Q4 2024 net sales $93M (+7% YoY); full year $349M (+9% YoY). Adjusted EBITDA margin 21% for Q4.
- GAAP net income Q4 $7M ($0.05 EPS); full year $42M. Cash $104M at Dec 31, net cash $86M.
- 2025 outlook: net sales growth at least high single-digits, Adjusted EBITDA margin above 20%.
- SG&A increased to $61M in Q4 from $54M a year ago; CEO cites Medicare disruption but remains confident.

## SEC filing metadata
- accession: 0001376339-25-000011
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/0001376339-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000011/mdxg-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-25-000011
- JSON: https://secwatch.observer/filing/0001376339-25-000011.json
- Plain text: https://secwatch.observer/filing/0001376339-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.